Please login to the form below

Not currently logged in
Email:
Password:

Sarepta

This page shows the latest Sarepta news and features for those working in and with pharma, biotech and healthcare.

FDA approves Sarepta rival NS Pharma’s Duchenne drug

FDA approves Sarepta rival NS Pharma’s Duchenne drug

The approval will see Viltepso enter a competitive market and likely head into a rivalry with Sarepta’s Vyondys 53 (golodirsen), which gained FDA approval last December.. ... Like NS Pharma, Sarepta is conducting a confirmatory trial of Vyondys 53

Latest news

More from news
Approximately 18 fully matching, plus 25 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
claire@dovetailstrategies.com

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

Switzerland
Switzerland: a life sciences hub
Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
Responding to dynamic shifts in value communications
OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
Doing what we can and having fun doing it: our fundraising month
Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...

Infographics